"The Impact of First-Line Rhythm Therapy on AF Progression"

NAUnknownINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

September 30, 2022

Study Completion Date

November 30, 2022

Conditions
Atrial Fibrillation
Interventions
PROCEDURE

Cryoballoon-based PVI

Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.

DRUG

Anti-Arrhythmic Drug Therapy

Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.

Trial Locations (18)

Unknown

Libin CV, Calgary

Royal Alexandra, Edmonton

St Paul's Hospital, Vancouver

Vancouver General, Vancouver

Royal Jubillee, Victoria

QE II, Halifax

Hamilton Health Sciences, Hamilton

St. Mary's, Kitchener

LHSC, London

Southlake, Newmarket

Ottawa Hospital, Ottawa

Rouge Valley, Scarborough Village

St. Michael's, Toronto

McGill, Montreal

Sacre-Coeur, Montreal

Laval, Québec

CHUS Le Centre hospitalier universitaire de Sherbrooke, Sherbrooke

U Saskatchewan, Saskatoon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ottawa Heart Institute Research Corporation

OTHER

collaborator

Medtronic

INDUSTRY

lead

University of British Columbia

OTHER